Factors associated with significant liver necroinflammation in chronic hepatitis B patients with cirrhosis.
We determined the association between various clinical parameters and significant liver necroinflammation in patients with chronic hepatitis B (CHB) related cirrhosis. Two hundred patients with CHB related cirrhosis were recruited in the final analysis. Clinical laboratory values and characteristics were obtained from the medical record. We performed analyses of the relationships between independent variables and significant liver necroinflammation by using binary logistic regression analysis and discriminant analysis. Significant liver necroinflammation (grade≥2) was found in 58.0% (80/138) of antiviral therapy patients and 48.4% (30/62) of non antiviral therapy patients respectively. Also, there were some significant differences in serum hepatitis B surface antigen (HBsAg), serum hepatitis B e antigen (HBeAg) and serum hepatitis B virus (HBV) DNA between antiviral therapy and non antiviral therapy patients. After that, aspartate aminotransferase (AST), total bilirubin (TBIL), total bile acid (TBA), prothrombin time (PT), aspartate aminotransferase to platelet ratio index (APRI) and serum HBV DNA were confirmed as independent predictors of significant liver necroinflammation in CHB patients with cirrhosis by univariate analysis and multivariate analysis (p = 0.002, 0.044, 0.001, 0.014, 0.01 and 0.02 respectively). Finally, receiver operating characteristic (ROC) curve analysis and discriminant analysis validated that these six variables together have strong predictive power to evaluate significant liver necroinflammation.
Department of Infectious Diseases and Hepatology, Huashan Hospital, Fudan University, Shanghai 200040, China.
Sheng-Sen
SS
Chen
Department of Infectious Diseases and Hepatology, Huashan Hospital, Fudan University, Shanghai 200040, China.
Kang-Kang
KK
Yu
Department of Infectious Diseases and Hepatology, Huashan Hospital, Fudan University, Shanghai 200040, China.
Qing-Xia
QX
Ling
Department of Infectious Diseases and Hepatology, Huashan Hospital, Fudan University, Shanghai 200040, China.
Chong
C
Huang
Department of Infectious Diseases and Hepatology, Huashan Hospital, Fudan University, Shanghai 200040, China.
Ning
N
Li
Department of Infectious Diseases and Hepatology, Huashan Hospital, Fudan University, Shanghai 200040, China.
Jian-Ming
JM
Zheng
Department of Infectious Diseases and Hepatology, Huashan Hospital, Fudan University, Shanghai 200040, China.
Su-Xia
SX
Bao
Department of Infectious Diseases and Hepatology, Huashan Hospital, Fudan University, Shanghai 200040, China.
Qi
Q
Cheng
Department of Infectious Diseases and Hepatology, Huashan Hospital, Fudan University, Shanghai 200040, China.
Meng-Qi
MQ
Zhu
Department of Infectious Diseases and Hepatology, Huashan Hospital, Fudan University, Shanghai 200040, China.
Ming-Quan
MQ
Chen
D000328:Adult; D005260:Female; D006511:Hepatitis B Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000235:genetics / Q000302:isolation & purification; D019694:Hepatitis B, Chronic / Q000097:blood / Q000150:complications*; D006801:Humans; D007249:Inflammation / Q000150:complications; D008099:Liver / Q000473:pathology*; D008103:Liver Cirrhosis / Q000150:complications* / Q000473:pathology; D008875:Middle Aged; D009336:Necrosis / Q000150:complications; D012372:ROC Curve; D012189:Retrospective Studies
D006511:Hepatitis B Antigens